Earnings summaries and quarterly performance for Quanterix.
Executive leadership at Quanterix.
Board of directors at Quanterix.
Research analysts who have asked questions during Quanterix earnings calls.
Daniel Brennan
TD Cowen
3 questions for QTRX
Also covers: A, ADPT, AVTR +24 more
KM
Kyle Mikson
Canaccord Genuity
3 questions for QTRX
Also covers: AKYA, BDSX, CSTL +12 more
PS
Puneet Souda
Leerink Partners
3 questions for QTRX
Also covers: A, ABCL, BRKR +20 more
SJ
Sung Ji Nam
Scotiabank
3 questions for QTRX
Also covers: ADPT, BDSX, BNGO +9 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for QTRX
Also covers: A, ADPT, AVTR +21 more
Thomas DeBourcy
Nephron Research
2 questions for QTRX
Also covers: CDNA, NEOG, TWST +2 more
JA
Jake Allen
Goldman Sachs
1 question for QTRX
Also covers: PACB
Michael Cherny
Leerink Partners
1 question for QTRX
Also covers: ACCD, ALGN, CAH +18 more
Recent press releases and 8-K filings for QTRX.
QIAGEN Sets 2026 Priorities and Targets $2 Billion in Pillar Sales by 2028
QTRX
New Projects/Investments
Product Launch
Guidance Update
- QIAGEN announced its 2026 priorities focused on advancing product commercialization, regulatory milestones, and automation system innovations to support its goal of at least $2 billion in combined annual pillar sales by 2028.
- The company's five growth pillars are Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics, and QuantiFERON for latent tuberculosis testing.
- In December 2025, QIAGEN acquired Parse Biosciences, which is expected to contribute approximately $40 million in sales in 2026.
- Key initiatives for 2026 include launching three new sample preparation systems (QIAsymphony Connect, QIAsprint Connect, QIAmini), expanding the QIAstat-Dx test menu with new regulatory submissions, and introducing new QIAcuity digital PCR gene expression assays.
- QIAGEN also plans to roll out new AI capabilities for pharmaceutical R&D and develop a fifth generation of its QuantiFERON test, with updates planned during 2026.
8 days ago
Quanterix Appoints New CEO and Updates 2025 Guidance
QTRX
CEO Change
Executive Compensation
Guidance Update
- Quanterix Corporation appointed Everett Cunningham as President and Chief Executive Officer, effective January 19, 2026.
- Masoud Toloue resigned from his roles as President, CEO, and Board member, effective January 19, 2026, and will serve in an advisory capacity during the transition.
- Mr. Cunningham's compensation package includes an annual base salary of $750,000, an annual performance bonus target of up to 100% of his base salary, a $600,000 sign-on cash payment, and long-term equity incentive awards consisting of 1,070,000 Time-Based RSUs and 813,750 Performance-Based RSUs.
- The company expects to exceed its guidance for revenue and cash for the full year 2025.
Jan 8, 2026, 9:46 PM
Quanterix Appoints New CEO and Updates 2025 Guidance
QTRX
CEO Change
Management Change
Guidance Update
- Quanterix has appointed Everett Cunningham as President and CEO, effective January 19, 2026, succeeding Masoud Toloue.
- Mr. Cunningham previously served as Chief Commercial Officer at Illumina and Exact Sciences.
- The company announced it expects to exceed its revenue and cash guidance for the full year 2025.
- In connection with his appointment, Mr. Cunningham will receive long-term equity incentive awards, including 1,070,000 time-based Restricted Stock Units (RSUs) and 813,750 performance-based RSUs.
Jan 8, 2026, 9:30 PM
QT Imaging Announces 2025 Scanner Shipments and Revenue Guidance Achievement
QTRX
Guidance Update
Revenue Acceleration/Inflection
- QT Imaging shipped 40 Breast Acoustic CT™ scanners in 2025, successfully meeting its revenue guidance of more than $18 million.
- This performance represents a year-over-year revenue growth of more than 285%, with scanner shipments increasing from 12 in 2024 to 40 in 2025.
- The company anticipates ending 2025 in a strong financial position, projecting year-end cash of at least $10 million, a significant increase from $1.2 million at the end of 2024.
- QT Imaging reiterates its 2026 revenue target of $39 million, which is based on the planned shipment of 80 scanners.
Dec 24, 2025, 1:30 PM
Quanterix Announces Board and Leadership Changes
QTRX
Board Change
Management Change
Hiring
- Quanterix Corporation announced significant board and leadership changes, effective November 20, 2025, to support its next stage of growth.
- Paul Meister and David Walt, Ph.D., retired from the Board of Directors.
- The Board appointed Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., as new directors. Dr. Hampton will serve on the Audit and Compensation Committees, and Dr. Sachs will serve on the Compensation Committee.
- Bill Donnelly was appointed Executive Chair of the Board, and Jeffrey Elliott was appointed Lead Independent Director.
- Following these changes, the Quanterix Board now comprises nine members, with seven being independent.
Nov 20, 2025, 10:22 PM
Quanterix Reports Q3 2025 Results and Integration Progress
QTRX
Earnings
Guidance Update
M&A
- Quanterix reported $40.2 million in total revenue for Q3 2025, representing a 12% increase year over year, with Simoa contributing $23 million and Spatial $17.2 million.
- The company has realized $67 million of its $85 million in targeted cost synergies following the Akoya acquisition.
- Quanterix expects to finish 2025 with approximately $120 million in cash and no debt, and anticipates being cash flow breakeven in 2026.
- The full-year 2025 revenue guidance remains unchanged at $130-$135 million, with a pro forma revenue of $165-$170 million if the companies were combined for the full year.
- Significant R&D investments, totaling approximately $27 million year-to-date, are focused on Alzheimer's diagnostics and new assays, with an early access program for Simoa ONE planned.
Nov 10, 2025, 9:30 PM
Quanterix Reports Q3 2025 Results and Provides 2025 Guidance
QTRX
Earnings
Guidance Update
M&A
- Quanterix reported Q3 2025 revenue of $40.2 million, marking a 12% increase compared to Q3 2024.
- The company provided full-year 2025 revenue guidance of $130 million to $135 million and expects GAAP and Adjusted Gross Margin to be between 45% to 47%.
- Quanterix anticipates ending 2025 with approximately $120 million of cash and no debt.
- Through Akoya integration, the company expects $85 million in synergy and cost actions in 2026, aiming for cash flow breakeven performance in 2026, with $67 million of these annualized cost reductions already implemented.
Nov 10, 2025, 9:30 PM
Quanterix Reports Q3 2025 Financial Results
QTRX
Earnings
Guidance Update
M&A
- Quanterix Corporation reported Q3 2025 revenue of $40.2 million, an increase of 12.3% compared to the prior year.
- The company's GAAP gross margin for Q3 2025 was 42.8%, with an Adjusted EBITDA (non-GAAP) loss of $11.9 million.
- Quanterix ended the third quarter with $138.1 million in cash, cash equivalents, marketable securities, and restricted cash, and anticipates ending 2025 with approximately $120 million.
- The company reaffirmed its 2025 revenue guidance of $130 to $135 million and expects to achieve cash flow break-even in 2026, driven by $67 million in cost synergies already implemented from the Akoya integration.
Nov 10, 2025, 9:08 PM
QT Imaging Secures Funding to Repurchase Warrants
QTRX
Debt Issuance
Share Buyback
- QT Imaging Holdings, Inc. received $5.0 million in new funding from Lynrock Lake Master Fund LP.
- This financing was obtained through a restated and amended senior secured term loan.
- The net proceeds were used to repurchase and cancel all warrants held by YA II PN, Ltd. (Yorkville).
- These warrants represented 15,000,000 shares of the Company’s Common Stock at an exercise price of $0.40 per share.
- QT Imaging's CEO, Dr. Raluca Dinu, stated that the transaction reflects confidence in the business's future outlook and is believed to enhance long-term shareholder value.
Aug 27, 2025, 12:30 PM
Quarterly earnings call transcripts for Quanterix.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more